ZEISS continues to drive digital era forward in ophthalmology; celebrates 2 million digitally-planned cataract cases in the U.S. alone
Showcasing at ASCRS 2025: More than 2 million cases planned with ZEISS VERACITY…
World Hemophilia Day 2025 – April 17, 2025 – “Access for all: Women and girls bleed too”
MONTREAL, April 17, 2025 /PRNewswire/ -- On April 17, 2025, the global…
![Norgine welcomes TGA registration in Australia of IFINWIL (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1]](https://i3.wp.com/mma.prnewswire.com/media/597589/4648918/Norgine_Logo.jpg?p=thumbnail&w=420&resize=420,280&ssl=1 "Norgine welcomes TGA registration in Australia of IFINWIL (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1]"){kind=logo}
Norgine welcomes TGA registration in Australia of IFINWIL (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1]
IFINWIL®: now TGA registered in AustraliaChildren diagnosed with neuroblastoma are on average just…
Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canadas Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYBs Acute Treatment of Migraine With or Without Aura in Cana
April 15, 2025 09:00 ET | Source: Scilex Holding Company ELYXYB® is…
NeuroOne OneRF Technology Success Story Featured on Fox News
Pediatric Patient Treated with OneRF® Ablation System Goes From Up to 10…
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document
Châtillon, France, April 11, 2025 DBV Technologies announces filing of 2024 Annual…
Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting
April 10, 2025 16:05 ET | Source: Protara Therapeutics NEW YORK, April…
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimers Disease
ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified…
ENHERTU Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy
Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority…
NCCN 2025 Annual Conference Illustrates the Critical Impact of Cancer Research on Improving Lives
The National Comprehensive Cancer Network celebrated its 30th anniversary with a series…